Disc Medicine, Inc. (IRON) Stock Price & How to Invest
Short answer
You can invest in Disc Medicine (IRON) by buying shares or fractional shares at any major broker, through a biotech ETF that holds it, or as one holding in a thematic basket. Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for serious hematologic (blood) diseases, and like most pre-revenue biotechs its share price is driven by clinical trial readouts and FDA decisions rather than by sales or profits.
IRON stock price
As of 2026-07-08, Disc Medicine, Inc. (IRON) last closed at $80.06, up 43.3% over the past year. Over the past 52 weeks it has traded between $55.86 and $94.11.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Disc Medicine, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Disc Medicine, Inc. (IRON) do?
Disc Medicine (Nasdaq: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. Its programs aim to modify the biological pathways behind red blood cell formation and function, principally heme biosynthesis and iron homeostasis. The lead pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), DISC-0974 (an anti-hemojuvelin antibody) for anemia of myelofibrosis, and DISC-3405 (an anti-TMPRSS6 antibody) being studied in conditions like polycythemia vera and sickle cell disease. The current company was formed when Disc Medicine reverse-merged into Gemini Therapeutics in December 2022 and began trading under the ticker IRON.
As a clinical-stage biotech, Disc Medicine generates essentially no product revenue and runs at a net loss as it funds research and clinical trials. The investment picture is therefore about pipeline probability and cash: the company reported strong clinical updates in 2026, including positive Phase 2 RALLY-MF anemia data for DISC-0974 and continued EPP work, but the FDA issued a complete response letter for bitopertin in February 2026, finding existing data insufficient for accelerated approval, pushing the company toward its Phase 3 APOLLO trial (topline expected in Q4 2026) for a potential traditional approval. Backed by roughly $791 million in cash against an annual burn near $180 million, Disc has multiple years of runway, but its value ultimately depends on whether these programs succeed in trials and reach the market.
What's driving Disc Medicine, Inc. (IRON)?
1. Bitopertin and the APOLLO Phase 3 catalyst.
Bitopertin in erythropoietic porphyrias is Disc's most advanced program and its nearest-term commercial opportunity. After the FDA's February 2026 complete response letter declined accelerated approval, the company is running the Phase 3 APOLLO trial with topline data expected in the fourth quarter of 2026 to support a potential traditional approval. This readout is a major binary event that could meaningfully move the stock in either direction.
2. DISC-0974 in anemia of myelofibrosis.
DISC-0974 is an anti-hemojuvelin antibody targeting anemia in myelofibrosis, a large unmet need. Phase 2 RALLY-MF data presented in 2026 showed meaningful, durable hemoglobin gains and transfusion reductions across subgroups, including patients on JAK inhibitors, with generally favorable tolerability. Updated Phase 2 data are expected in the second half of 2026, followed by an End of Phase 2 meeting that would set up later-stage development.
3. Broader hematology pipeline optionality.
DISC-3405, an anti-TMPRSS6 antibody, is being studied in polycythemia vera (Phase 2) and sickle cell disease (Phase 1b), with early data showing increased hepcidin and reduced serum iron. A pipeline spanning multiple mechanisms and blood disorders gives Disc several independent shots on goal. Each additional program adds potential value but also adds cost and execution risk before any of them are proven.
4. Strong balance sheet and cash runway.
Disc reported roughly $791 million of cash and investments against about $31 million of debt, giving a large net cash position relative to its size. With an annual operating burn near $180 million, that supports multiple years of runway to fund pivotal trials without immediate financing pressure. A well-funded balance sheet reduces the risk of a forced, dilutive raise at a weak share price, though future offerings are still common in biotech.
What are the risks to Disc Medicine, Inc. (IRON)?
Disc Medicine is a clinical-stage company with essentially no product revenue, so it is not profitable and its value rests on trials that can fail. Outcomes are binary: the February 2026 complete response letter for bitopertin is a reminder that positive early data does not guarantee approval, and a negative Phase 3 APOLLO or DISC-0974 readout could sharply reduce the stock. The company burns cash and may need to raise capital in the future, which can dilute existing shareholders. Even successful drugs face commercial risk in small rare-disease markets, competition from established therapies, manufacturing and reimbursement hurdles, and the concentration risk of a pipeline built around a few key programs. The stock is highly volatile and pays no dividend.
How is Disc Medicine, Inc. (IRON) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Disc Medicine, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$0 (pre-revenue, clinical stage)
- Net loss (approx, TTM): ~$180 million
- Cash and investments: ~$791 million
- Net cash position: ~$760 million (~$20/share)
- Shares outstanding: ~38 million
- Market cap: ~$2.9 billion
As a clinical-stage biotech, Disc has no meaningful product sales, so traditional metrics like P/E do not apply and the company is valued on its pipeline's expected value and its cash. Its roughly $791 million cash pile is large relative to its market cap, meaning a big share of the value is the balance sheet plus the option value of its programs. The market cap and share price can swing sharply around trial data and FDA decisions.
Who competes with Disc Medicine, Inc. (IRON)?
Rare hematology and iron-pathway biotechs
Companies developing therapies for anemias and iron-metabolism disorders, such as Agios Pharmaceuticals (mitapivat/PYRUKYND), Keros Therapeutics, and Protagonist Therapeutics. They compete with Disc for the same patient populations, clinical talent, and investor attention in hematology.
Myelofibrosis and blood-cancer players
Firms addressing myelofibrosis and its anemia, including GSK (momelotinib/Ojjaara), Incyte (ruxolitinib/Jakafi), and Geron. DISC-0974 targets anemia in these patients, so approved and investigational therapies in this space are direct commercial competition.
Porphyria and rare-disease specialists
Companies with approved or developing treatments touching porphyrias and related rare diseases, such as Alnylam Pharmaceuticals (givosiran/Givlaari) and Recordati (afamelanotide/Scenesse for EPP). Bitopertin would enter markets where some of these therapies are already established.
How to invest in Disc Medicine, Inc. (IRON)
There are three common ways to get IRON exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so IRON sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where IRON fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Disc Medicine, Inc. (IRON)
Disc Medicine is a clinical-stage hematology biotech with no product revenue yet, a large cash cushion, and a value that hinges on binary trial and regulatory outcomes across its lead programs. It tends to behave as a high-volatility, event-driven biotech stock: large swings around data readouts and FDA milestones, with no dividend and meaningful risk of loss if key programs fail.
More on Disc Medicine, Inc. (IRON)
Whether IRON is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IRON a buy?, and where the stock could go from here in the IRON stock forecast.
For income investors, whether IRON pays a dividend and how the payout looks is covered in does IRON pay a dividend?
Build a basket around IRON with Walnut
Use Disc Medicine, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Disc Medicine (IRON) do?
+
Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for serious blood (hematologic) diseases. Its programs target the pathways behind red blood cell formation and iron balance, including therapies for erythropoietic porphyrias and anemia of myelofibrosis.
Is IRON profitable?
+
No. As a clinical-stage biotech, Disc has essentially no product revenue and runs at a net loss (roughly $180 million over the trailing year) as it funds research and clinical trials. Profitability would depend on getting drugs approved and successfully launched.
Does IRON pay a dividend?
+
No. Disc Medicine does not pay a dividend. Like most pre-revenue biotechs, it reinvests all of its capital into research and development rather than returning cash to shareholders.
What are Disc Medicine's lead drug programs?
+
The lead programs are bitopertin for erythropoietic porphyrias (EPP and XLP), DISC-0974 for anemia of myelofibrosis, and DISC-3405 for conditions such as polycythemia vera and sickle cell disease. Bitopertin is the most advanced program.
What happened with bitopertin and the FDA?
+
In February 2026 the FDA issued a complete response letter, finding the existing data insufficient to support accelerated approval. Disc is now running the Phase 3 APOLLO trial, with topline data expected in the fourth quarter of 2026, to seek a potential traditional approval.
How much cash does Disc Medicine have?
+
The company reported roughly $791 million in cash and investments against about $31 million of debt, a large net cash position relative to its size. Against an annual burn near $180 million, that supports several years of runway to fund its trials.
Why is IRON stock so volatile?
+
Its value depends on binary events like clinical trial readouts and FDA decisions rather than on sales or profits. A single positive or negative result can cause large price swings, which is typical for clinical-stage biotech stocks.
How can I invest in IRON?
+
You can buy Disc Medicine shares or fractional shares through any major brokerage, hold it via a biotech or small-cap ETF that includes it, or track it as one holding in a thematic basket. Walnut is not an investment adviser, and biotech stocks carry meaningful risk of loss.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Disc Medicine, Inc.'s investor relations page or your broker before making investment decisions.